Cancer drugs are becoming increasingly expensive, with some of the most costly drugs priced at over $12,000 per month. In fact, the number of new cancer treatment drugs with prices exceeding $200,000 per year is on the rise, making up 44% of drugs launched in the past 5 years. According to a recent report from Memorial Sloan Kettering Cancer Center, five such drugs have exorbitant prices.
Xofigo, approved by the FDA in 2013 to treat late-stage prostate cancer, costs $12,600 per month. Cyramza, manufactured by Eli Lilly for stomach and non-small cell lung cancer, costs $13,200 per month. Zykadia, from Novartis, treats late-stage non-small cell lung cancer and costs over $13,600 per month. Lenvima, approved for thyroid cancer, costs $13,900 per month. Blincyto, a drug for rare acute lymphoblastic leukemia, costs $64,200 per month.
The high cost of cancer drugs can be attributed to several factors. Firstly
